M S Ewer

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events
    Michael S Ewer
    The University of Texas MD Anderson Cancer Center, Houston, TX, United States Electronic address
    Eur J Cancer 50:2162-70. 2014
  2. pmc Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
    Atiar M Rahman
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Nanomedicine 2:567-83. 2007
  3. doi request reprint Enigmas regarding the true extent and impact of tyrosine kinase inhibitor-related cardiotoxicity
    Michael S Ewer
    The University of Texas MD Anderson Cancer Center, The Department of Cardiology, Houston, TX, USA
    Expert Opin Drug Saf 12:611-4. 2013
  4. doi request reprint A historical perspective of anthracycline cardiotoxicity
    Michael S Ewer
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Heart Fail Clin 7:363-72. 2011
  5. pmc Cardiac dysfunction after cancer treatment
    Michael S Ewer
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Tex Heart Inst J 38:248-52. 2011
  6. doi request reprint Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
    Michael S Ewer
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Cardiol 7:564-75. 2010
  7. doi request reprint A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health
    Michael S Ewer
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1813-26. 2009
  8. ncbi request reprint Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation
    M S Ewer
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer 92:1905-12. 2001
  9. ncbi request reprint Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer
    Michael S Ewer
    Department of Cardiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:600-7. 2007
  10. ncbi request reprint Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
    Michael S Ewer
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7820-6. 2005

Detail Information

Publications26

  1. ncbi request reprint Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events
    Michael S Ewer
    The University of Texas MD Anderson Cancer Center, Houston, TX, United States Electronic address
    Eur J Cancer 50:2162-70. 2014
    ..To define cardiovascular (CV) risk and reversibility of cardiac events in patients who received sunitinib versus comparator treatment (interferon-alfa or placebo)...
  2. pmc Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
    Atiar M Rahman
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Nanomedicine 2:567-83. 2007
    ..In the case of liposomal doxorubicin, cardiotoxicity is reduced significantly. This review summarizes the important information on the liposomal preparation of anthracyclines...
  3. doi request reprint Enigmas regarding the true extent and impact of tyrosine kinase inhibitor-related cardiotoxicity
    Michael S Ewer
    The University of Texas MD Anderson Cancer Center, The Department of Cardiology, Houston, TX, USA
    Expert Opin Drug Saf 12:611-4. 2013
    ..Some mechanistic considerations regarding type II toxicity, albeit not categorically proven, are presented. ..
  4. doi request reprint A historical perspective of anthracycline cardiotoxicity
    Michael S Ewer
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Heart Fail Clin 7:363-72. 2011
    ....
  5. pmc Cardiac dysfunction after cancer treatment
    Michael S Ewer
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Tex Heart Inst J 38:248-52. 2011
    ..It is to this end that our working together has brought us to our present understanding. In the future, we may expect onco-cardiology to play an even greater role in the care of cancer patients...
  6. doi request reprint Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
    Michael S Ewer
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Cardiol 7:564-75. 2010
    ..In an effort to maximize both quality of life and survival, cardiologists and oncologists should collaborate with the aim of balancing the risks of cardiotoxicity with the benefits of oncologic therapy...
  7. doi request reprint A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health
    Michael S Ewer
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1813-26. 2009
    ..Cancer 2009. (c) 2009 American Cancer Society...
  8. ncbi request reprint Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation
    M S Ewer
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer 92:1905-12. 2001
    ....
  9. ncbi request reprint Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer
    Michael S Ewer
    Department of Cardiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:600-7. 2007
    ....
  10. ncbi request reprint Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
    Michael S Ewer
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7820-6. 2005
    ..However, trastuzumab is associated with cardiotoxicity that has not yet been fully explored. We present our experience with patients who developed trastuzumab-related cardiotoxicity...
  11. ncbi request reprint Cardiac safety of liposomal anthracyclines
    Michael S Ewer
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Oncol 31:161-81. 2004
    ..Further results are eagerly awaited from ongoing controlled trials of cardiac safety with long-term liposomal anthracycline therapy, either alone or in combination with other potentially cardiotoxic agents...
  12. pmc Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs
    A Naing
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 23:2960-3. 2012
    ..Prolongation of the corrected QT interval (QTc) by noncardiac drugs is the most common cause of drug development delays, nonapprovals and postmarketing withdrawals by the US Food and Drug Administration...
  13. ncbi request reprint Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs
    Robin L Jones
    Royal Marsden Hospital, Department of Medicine, Fulham Road, London SW3 6JJ, UK
    Expert Rev Anticancer Ther 6:1249-69. 2006
    ..Ischemia and rhythm abnormalities are treated symptomatically in most cases. Knowledge of these toxicities can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient...
  14. ncbi request reprint Outcome and cost implications of cardiopulmonary resuscitation in the medical intensive care unit of a comprehensive cancer center
    Susannah K Wallace
    Department of Medical Informatics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 214, Houston, TX 77030, USA
    Support Care Cancer 10:425-9. 2002
    ..Providing assurances that care will remain appropriate, aggressive, and in accordance with the patient's and family's wishes can optimize compassionate care while avoiding futile life-sustaining interventions...
  15. ncbi request reprint Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
    Sandra M Swain
    National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20889, USA
    Cancer 97:2869-79. 2003
    ....
  16. ncbi request reprint Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management
    Edward T H Yeh
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Tex 77030 4095, USA
    Circulation 109:3122-31. 2004
    ..Further research will be required to more accurately predict which patients are at risk for developing cardiotoxicity. In addition, management plans, as well as strategies to reduce cardiotoxicity, need to be developed...
  17. doi request reprint Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    Mayo Clin Proc 83:679-86. 2008
    ..To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR (ERBB1) and HER2 inhibitor, using prospective data collected in 44 clinical studies...
  18. ncbi request reprint Cardiotoxicity profile of trastuzumab
    Steven M Ewer
    The Division of Cardiology, Washington University School of Medicine, St Louis, Missouri, USA
    Drug Saf 31:459-67. 2008
    ..Increased vigilance is appropriate for higher risk patients...
  19. ncbi request reprint Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
    Michael S Ewer
    J Clin Oncol 26:1201-3. 2008
  20. ncbi request reprint Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  21. ncbi request reprint Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Michael S Ewer
    J Clin Oncol 25:5532-3; author reply 5533-4. 2007
  22. ncbi request reprint Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity
    Michael S Ewer
    Departments of Cardiology and Clinical Cancer Prevention and Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:2900-2. 2005
  23. ncbi request reprint Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  24. ncbi request reprint Anthracycline cardiotoxicity
    Robin L Jones
    Royal Marsden Hospital, Department of Medicine, Fulham Road, London, SW3 6JJ, UK
    Expert Opin Drug Saf 5:791-809. 2006
    ..Further work is required to identify patients at increased risk of cardiotoxicity and to develop novel methods of protecting and treating this adverse effect...
  25. ncbi request reprint The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight
    Michael S Ewer
    Eur J Cancer 43:2024-5. 2007
  26. ncbi request reprint Exercise echocardiography reflects cumulative anthracycline exposure during childhood
    Michael S Ewer
    Pediatr Blood Cancer 42:554-5. 2004